Paroxysmal kinesigenic dyskinesia (PKD), a rare paroxysmal movement disorder often misdiagnosed as epilepsy, is characterized by recurrent, brief dyskinesia attacks triggered by sudden voluntary movement. Pathophysiological mechanism of PKD remains not well understood. Ion channelopathy has been suggested, since the disease responds well to ion channel blockers. Mutations in proline-rich transmembrane protein 2 (PRRT2) were recently identified in patients with familial PKD. To extend these genetic reports, we studied a family with clinical manifestations of familial PKD responding well to low dose carbamazepine. Therapeutic dose ranged from 1.5 to 2.0 mg/ kg/day, below that in seizure control. One insertion mutation c.649_650insC (p.P217fsX7) was identified in three patients of the family. This study avers PRRT2's high sensitivity for PKD phenotype. Identification of genes underlying pathogenesis will enhance diagnosis and treatment. Function of PRRT2 and its role in PKD warrant further investigation.
Introduction
Paroxysmal kinesigenic dyskinesia (PKD, OMIM 128000) is a rare paroxysmal movement disorder, often misdiagnosed as epilepsy and characterized by recurrent, brief attacks of dyskinesia triggered by sudden voluntary movement. Onset is around early teenage [1] . Sudden movement after a prolonged rest period is the most common precipitating factor, duration of attack usually brief, lasting seconds up to five minutes [2] [3] [4] [5] . They can occur many times daily, but frequency and severity of attack seem to decrease with age. Brain imaging and electroencephalography (EEG) of such patients are usually normal [1, 6] Pathophysiological mechanism of PKD remains not well understood, but studies suggest it as a type of reflex epilepsy [7] [8] [9] . Ion channelopathy has been cited; this disease responds well to ion channel blockers [10] . Mutations of proline-rich transmembrane protein 2 (PRRT2) have recently been identified in cases of familial PKD [11] [12] [13] [14] [15] . PRRT2 protein, expressed strongly in a developing nervous system and localized to axons, interacts with synaptic protein SNAP 25, and may play a role in synaptic regulation [11, 14] . We report a family with clinical manifestations of familial PKD responding to low-dose CBZ. One insertion mutation c.649_650insC (p.P217fsX7) was identified in three patients of the family.
2.
Patients and Methods
Clinical Report
A twelve-year-old male had two-year history of paroxysmal movement disorder induced by sudden movement or brief exercise; birth, delivery, and development were unremarkable, without significant medical history. Attacks were first evident at age 10, after sudden arm movements; these entailed dystonic flexion and greater internal rotation of left arm and left leg, as well as finger posturing. He was fully aware of his surroundings during the attacks of paroxysmal kinesigenic dyskinesia. At 200 mg daily (10 mg/kg/day), the patient attained complete resolution of signs that has persisted for the past seven years, no side effects from medication. His father and brother, both diagnosed as PKD, had the same symptoms (Fig. A) ; Table 1 summarizes clinical manifestations. Both were prescribed CBZ as monotherapy (dosage 200 mg/day) to attain total resolution for the past seven years. (Fig. B) . 
Discussion
PKD is the most common form of paroxysmal dyskinesia. Clinical features of our patients resembled cases reported previously: e.g., precipitating factors, patterns of attack, age of onset [1, 2, 4, 5, 6, 16] . Overall, family members had clinical features similar to those of individuals in literature. Controversial surrounds pathophysiology of involuntary movements. It is still uncertain whether symptoms relate to epileptic seizure or are dysfunction of basal ganglia [17, 18, 19] . Some propose this disorder as epileptic syndrome, based on prodromata preceding attacks, as well as its response to anticonvulsants. Interictal EEG abnormalities of reported PKD cases include sporadic epileptic discharge or slow rhythm [7, 8, 9] . None of our recordings showed any such abnormalities. Also, consciousness during attacks was always preserved. Patients with PKD attacks seem to respond well to anticonvulsants: lamotrigine, phenytoin, valproate, oxacarbazepine, and especially CBZ [5, 6, 20, 21, 22] , whose mechanism is blockade of ion conduction through voltagedependent ion channels of the neuron. Physiology of PKD is still uncertain, but ion channelopathy is considered; prior studies reported PKD patients sensitive to ion channel blockers like CBZ [6, 21] . CBZ is widely used, being inexpensive and broad-spectrum in seizure controls; we found 100mg/day effectively controlling PKD. Therapeutic dose ranged from 1. Seventeen PRRT2 mutations were recently identified in patients with familial or apparently sporadic PKD/IC from several ethnic groups [11] [12] [13] [14] [15] 23] , the vast majority (11/17) premature termination or frameshift mutation resulting in truncation of PRRT protein, the rest missense mutations. Interestingly, p.R217P*8 arose in about 80% of PKD patients with PRRT2 mutations [11] [12] [13] [14] [15] 23] . All identified families displayed autosomally dominant inheritance. Function of PRRT2 protein is poorly characterized. Recent in vivo and in vitro studies demonstrated that PRRT2 is highly expressed in the developing nervous system and localized on cell membrane, predominantly in axons [11, 14] . It is not surprising that truncating mutations can significantly reduce protein expression and/or cause loss of transmembrane property, which conceivably impairs PRRT2 protein function [11, 14] . This study highlights frequency of PRRT2 mutations in a Taiwanese cohort with idiopathic PKD. For this benign neurological condition, low dose of CBZ is adequate to provide good control.
